A tree does not file paperwork.
A mushroom does not hire counsel.
A root does not sit in a boardroom and explain its market potential.
Nature creates quietly.
Then man arrives with instruments, language, capital, and law.
He studies the plant. He isolates the compound. He changes the molecule. He stabilizes the extract. He invents a delivery system. He writes a claim. He files the patent.
Then the old medicine becomes new property.
That is the patent problem.
Not because every patent is theft.
Not because every laboratory is corrupt.
Not because traditional medicine is automatically safer, purer, or more ethical than modern pharmaceutical science.
The problem is deeper than that.
The problem is that the living world often creates the original intelligence, while the legal system rewards the person who translates that intelligence into something ownable.
The garden gives the clue.
The lab gets the asset.
Responsibility note: This article is educational and reflective. It is not legal, medical, or investment advice. Patent law is complex and varies by country. Natural products can be beneficial, harmful, contaminated, misused, or illegal depending on the substance, preparation, person, and place.
Nature Cannot Usually Be Owned Exactly as Found
Let us start clean.
In the United States, a natural thing is generally not patentable simply because someone discovered it.
USPTO guidance treats laws of nature, natural phenomena, and products of nature as judicial exceptions to patent eligibility.[1] The Supreme Court made this point clearly in Association for Molecular Pathology v. Myriad Genetics. A naturally occurring DNA segment is not patent eligible merely because it has been isolated, while complementary DNA, or cDNA, may be patent eligible because it is not naturally occurring in the same way.[2]
That distinction matters.
The law does not simply say, “Find a plant, own a plant.”
A person cannot walk into the forest, point at a mushroom, and claim ownership of the mushroom’s natural existence.
But the story does not end there.
A product of nature may be unpatentable as nature made it, while a human made variation, method, formulation, process, use, purified preparation with specific claimed properties, synthetic route, delivery system, or modified molecule may still become part of a patent strategy.
That is where the door opens.
The old medicine may not be patentable.
The translation might be.
The Translation Is Where the Money Lives
A plant does not fit easily into the modern property system.
It varies by soil, climate, season, harvest, storage, preparation, genetics, and relationship.
That makes it hard to standardize.
It also makes it hard to own.
A single compound fits the system better.
It can be named.
It can be measured.
It can be manufactured.
It can be tested.
It can be dosed.
It can be insured.
It can be defended.
It can be licensed.
It can be sold.
So the system keeps asking the same question:
Can this living complexity be narrowed into something protectable?
That is the move from plant to product.
Sometimes the move is genuinely useful. A standardized extract may be safer than a wildly variable preparation. A modified molecule may reduce toxicity. A delivery system may improve absorption. A synthetic route may prevent overharvesting. A purified compound may allow better research.
We should not pretend every act of translation is exploitation.
But we should also not pretend translation is neutral.
When a plant becomes a patentable asset, the question changes.
It is no longer only, “What helps the person?”
It becomes, “What can be owned?”
Slight Changes Can Matter
It is tempting to say companies make tiny alterations to natural compounds, patent them, and keep the same effect.
Sometimes the suspicion is understandable.
The incentive is real.
If a natural compound itself is difficult to protect, a modified version may be more commercially attractive. A small molecular change, formulation change, or delivery change may create a new legal and market position.
But we need to be honest.
Small changes are not always meaningless.
In chemistry, a small change can alter potency, duration, absorption, metabolism, stability, toxicity, storage, or the way the body handles a compound.
A slight change can make a medicine better.
It can also make it riskier.
And sometimes, yes, it may mainly make the product easier to own.
That is the uncomfortable zone.
Patent law is not supposed to reward cosmetic changes. A claimed invention still has to meet standards such as eligibility, novelty, usefulness, non obviousness, and adequate disclosure.[1]
But incentives shape attention.
When the strongest financial reward goes to the patentable version, research energy moves toward the patentable version.
The natural mixture becomes background.
The owned variation becomes the main event.
The Whole Plant Problem
Whole plants are difficult for modern medicine because they are not one thing.
They are many things at once.
A single plant may contain dozens or hundreds of compounds. Some may be active. Some may buffer others. Some may change absorption. Some may alter taste, digestion, smell, mood, inflammation, or metabolism. Some may do very little. Some may matter only in context.
Modern trials prefer clean variables.
Industry prefers clean assets.
Regulators prefer clear identity and dose.
Whole plant preparations resist all three.
That does not mean whole plants are always better. Sometimes the whole plant is too variable, too weak, too strong, too contaminated, too hard to dose, or too dangerous. Foxglove is natural. So is aconite. So is poison hemlock. Nature does not become gentle because we gave it spiritual lighting.
Still, whole plant complexity deserves respect.
In cannabis, the “entourage effect” is often used to describe the possibility that cannabinoids, terpenes, flavonoids, and other compounds may work together in ways that differ from isolated compounds. Reviews describe plausible mechanisms, while also warning that the evidence is still developing and the term is often stretched beyond what the data can prove.[3]
That is the mature view.
The plant may be more than one molecule.
The marketing may be more than the science.
Both can be true.
The System Prefers What It Can Count
The modern medical system likes clean answers.
One diagnosis.
One active ingredient.
One dose.
One target.
One endpoint.
One claim.
One product.
This can be useful.
It can also become a kind of blindness.
A person is not one pathway. A plant is not one molecule. A ceremony is not one variable. Food is not just calories. A medicine encounter is not only a biochemical event.
But the system prefers what it can count because counting creates control.
Control creates approval.
Approval creates reimbursement.
Reimbursement creates markets.
Markets create power.
So the living world gets filtered.
The parts that fit become medicine.
The parts that do not fit become folklore, placebo, alternative, wellness, anecdote, or noise.
This is not always conspiracy in the cartoon sense.
It is incentive.
A system can narrow reality without every person inside it waking up in the morning trying to deceive the world.
Traditional Knowledge Becomes Prior Art, If Someone Can Prove It
Patent law has a useful concept called prior art.
If something was already known, used, published, or obvious before the patent claim, that can matter. Traditional knowledge can be part of that story, but only if it can be documented in a form the system recognizes.
That is one reason the turmeric wound healing patent became such a famous example.
A U.S. patent had been granted for the use of turmeric in wound healing. India’s Council of Scientific and Industrial Research challenged it, presenting evidence that such uses of turmeric were already known in India. The patent was revoked in 1997 on grounds of obviousness.[4]
That story matters because it reveals the imbalance.
Traditional knowledge may exist for generations.
But if it lives in oral tradition, household practice, ceremony, local language, or community memory, the patent system may not see it clearly until someone translates it into its own evidentiary language.
Imagine that.
A grandmother’s medicine is not enough.
A village’s memory is not enough.
A practice held across centuries is not enough.
Not until it becomes searchable, citeable, documented, legible to officials, and useful in a legal challenge.
That is not just an administrative problem.
It is a worldview problem.
Disclosure Is Not the Same as Justice
In 2024, WIPO member states adopted a treaty on intellectual property, genetic resources, and associated traditional knowledge. The treaty creates a patent disclosure requirement when a claimed invention is based on genetic resources or associated traditional knowledge. Applicants must disclose the country of origin of the genetic resources, or the Indigenous Peoples or local community associated with the traditional knowledge when applicable.[5]
That is a meaningful step.
It says origin matters.
It says traditional knowledge should not be invisible.
It says the patent system can no longer pretend the world began at the laboratory door.
But disclosure is not the same as justice.
Naming the source does not automatically share the profit.
Acknowledging origin does not automatically restore land, sovereignty, access, or control.
A footnote is not reciprocity.
The Nagoya Protocol, which entered into force in 2014, aims at fair and equitable benefit sharing from the use of genetic resources.[6] That framework matters, but real justice still depends on implementation, consent, enforcement, local power, and whether communities actually benefit from the knowledge and biodiversity they have protected.
The future cannot stop at, “We disclosed where we got it.”
The deeper question is, “Did the people and places that carried the medicine share in the value created from it?”
The Word “Biopiracy” Exists for a Reason
Biopiracy is a strong word.
It should not be thrown around lazily.
But it exists because the pattern is real.
People from wealthy institutions enter biodiversity rich places. They study plants, microbes, fungi, genes, or traditional practices. They extract knowledge or samples. They convert what they find into papers, products, patents, careers, and investment value. Then the communities that preserved the relationship may receive little or nothing.
Sometimes this is legal.
That does not make it clean.
The neem patent controversy is one of the better known examples. The European Patent Office revoked a patent involving neem oil fungicidal use after challenge, and the case became a symbol in global debates over traditional knowledge and biopiracy.[7]
Again, the point is not that no invention occurred anywhere in the chain.
The point is that legal invention can sit on top of older relationship.
If the law only rewards the final translator, it can miss the people who kept the language alive.
The Pharmaceutical Incentive Is Not Curiosity Alone
Scientists may be curious.
Companies are not built on curiosity alone.
A pharmaceutical company has duties to investors. It must develop assets. It must protect markets. It must recover costs. It must defend exclusivity. It must survive failure. It must generate returns.
That structure shapes what gets studied.
A low cost plant preparation with limited patent protection may be less attractive than a proprietary compound with strong exclusivity. A dietary pattern may be less attractive than a pill. A community based practice may be less attractive than a device, formulation, or approved product. A natural mixture may be less attractive than a synthetic analogue.
This does not mean the patented product never helps.
It means we should stop pretending the research agenda is purely a map of human need.
It is also a map of economic possibility.
That is why some things remain under researched, even when people have used them for generations.
Not because they are useless.
Because nobody can build a large enough moat around them.
The Gentle Medicine Claim Needs Discipline
Many people experience natural preparations as gentler than pharmaceutical products.
That can be true in ordinary practice.
Food, tea, whole plant preparations, and traditional remedies may often be lower dose, slower moving, more relational, and less aggressive than isolated high potency compounds. A plant matrix may soften an effect. Ritual may slow use. The body may receive the medicine as part of a larger pattern, not as a single chemical command.
But we should not turn that into a sloppy law of nature.
Natural does not always mean gentle.
Concentrated essential oils can harm. Supplements can interact with prescriptions. Botanicals can affect liver enzymes. Some herbs are contraindicated during pregnancy. Some plants are poisonous. Some mushrooms can kill. Some psychoactive substances can destabilize vulnerable people.
A mature plant medicine culture must be brave enough to say two things at once:
The natural world may offer gentler, more complex, more relational ways of supporting human life.
And the natural world can hurt you if you approach it without knowledge.
That is not contradiction.
That is respect.
What Ownership Does to Imagination
Ownership changes imagination.
When a company owns a product, the world starts learning the product’s name.
The plant fades.
The lineage fades.
The ecological relationship fades.
The healer fades.
The kitchen fades.
The ceremony fades.
The people who carried the knowledge become background.
The bottle becomes the brand.
Then the brand becomes the medicine.
This is how a culture forgets.
Not all at once.
One label at a time.
One study at a time.
One patent at a time.
One advertisement at a time.
One doctor’s office at a time.
Eventually, people begin to believe medicine is something that comes from institutions, and nature is something that needs institutional permission to matter.
That is the spell.
The patent problem is not only legal.
It is spiritual.
It teaches people to see living intelligence as raw material until someone with money makes it official.
What Better Would Look Like
The answer is not to abolish patents tomorrow.
That would create its own problems. Some medicines require enormous investment. Some development risks are real. Some manufacturing breakthroughs deserve protection. Some companies do build useful tools that would not exist without incentives.
But better is possible.
Better means stronger disclosure of genetic resources and traditional knowledge.
Better means meaningful benefit sharing.
Better means refusing to treat Indigenous and local knowledge as free research.
Better means supporting open science when exclusivity is unnecessary.
Better means funding research into whole plant preparations, food, lifestyle, community care, and low profit interventions.
Better means protecting biodiversity.
Better means respecting ceremonial lineages.
Better means asking whether a patent improves access or simply creates a toll booth.
Better means remembering that ownership is not the highest form of relationship.
The garden does not need us to make it sacred.
It needs us to stop treating sacred things as unclaimed inventory.
Integration Note
The patent problem asks a simple question:
Who gets to own what nature already knew?
The honest answer is not simple.
Sometimes human beings truly invent. Sometimes chemistry improves what nature started. Sometimes a bottle can save a life. Sometimes a patent can help bring a medicine through the long road of development.
But sometimes the patent is the final lock placed on an old door.
Sometimes the living world gives the medicine, traditional people preserve the clue, and the modern system rewards the person who arrives last with paperwork.
We do not need to reject science to see the pattern.
We need science with memory.
We need medicine with humility.
We need innovation with reciprocity.
We need a future where the laboratory can still create, but where it bows when it enters the garden.
Research Notes & Further Reading
[1] United States Patent and Trademark Office. “MPEP § 2106: Patent Subject Matter Eligibility.”
Official USPTO guidance explaining judicial exceptions, including laws of nature, natural phenomena, and products of nature.
https://www.uspto.gov/web/offices/pac/mpep/s2106.html
[2] Supreme Court of the United States. “Association for Molecular Pathology v. Myriad Genetics, Inc.” 569 U.S. 576. 2013.
The Court held that naturally occurring DNA is not patent eligible merely because it has been isolated, while cDNA may be patent eligible because it is not naturally occurring.
https://supreme.justia.com/cases/federal/us/569/576/
[3] C. Christensen et al. “Decoding the Postulated Entourage Effect of Medicinal Cannabis: What It Is and What It Isn’t.” Biomedicines. 2023.
Balanced review of the entourage effect, possible mechanisms, limits of evidence, and marketing overreach.
https://pmc.ncbi.nlm.nih.gov/articles/PMC10452568/
[4] World Intellectual Property Organization. “Use of Turmeric in Wound Healing.”
WIPO case summary explaining the turmeric patent challenge and 1997 revocation based on obviousness and traditional knowledge evidence.
https://www.wipo.int/tk/en/docs/use-of-turmeric-in-wound-healing-e.pdf
[5] World Intellectual Property Organization. “WIPO Treaty on Intellectual Property, Genetic Resources and Associated Traditional Knowledge.” Adopted May 24, 2024.
Official treaty page describing mandatory disclosure requirements for claimed inventions based on genetic resources or associated traditional knowledge.
https://www.wipo.int/en/web/treaties/ip/gratk/index
[6] Convention on Biological Diversity. “The Nagoya Protocol on Access and Benefit-sharing.”
Official overview of the international agreement on fair and equitable sharing of benefits from the use of genetic resources.
https://www.cbd.int/access-benefit-sharing
[7] Cormac Sheridan. “EPO neem patent revocation revives biopiracy debate.” Nature Biotechnology. 2005.
Background on the neem patent revocation and the wider debate over traditional knowledge, compensation, and biopiracy.
https://pubmed.ncbi.nlm.nih.gov/15877054/
